PATENT CLAIM ANALYSIS

Application Number: 16043994
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["435", "007920"]

Abstract:
An object of the present invention is to provide a novel Pca determination method and a Pca malignancy determination method. The present invention is an invention relating to a “prostate carcinoma determination method, including determining the ratio of the amount of free prostate specific antigen, which has a glycan in which the terminal sialic acid residue of the glycan is α(2,3)-linked to a second galactose residue from the terminal of the glycan, to the amount of free PSA in a biological sample, and then determining that prostate carcinoma is developed or the probability of developing prostate carcinoma is high in the case where the ratio is 40% or higher.”

Claim (Index 15):
The postate carcinoma determination method according to  claim 6 , wherein the total PSA value in the biological sample is 4 ng/mL and equal to or less than 10 ng/mL.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 95.0
- Lexical Diversity: 1.93651
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14432902', '13505280', '15005964', '14203438', '10530972']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6414707508664061
- 35 USC 102 Novelty (BERT): 0.5487108147422318
- Combined Prediction Score: 0.6321947572539887
- Mean Citation Score: 304.047912
- Max Citation Score: 460.5301
- Similarity Product: 272.7908077367008

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test